China Resources Boya Bio-pharmaceutical Group Co.,Ltd

SZSE:300294 Stock Report

Market Cap: CN¥16.8b

China Resources Boya Bio-pharmaceutical GroupLtd Future Growth

Future criteria checks 3/6

China Resources Boya Bio-pharmaceutical GroupLtd is forecast to grow earnings and revenue by 31.2% and 5.3% per annum respectively. EPS is expected to grow by 31.3% per annum. Return on equity is forecast to be 7.9% in 3 years.

Key information

31.2%

Earnings growth rate

31.3%

EPS growth rate

Biotechs earnings growth38.6%
Revenue growth rate5.3%
Future return on equity7.9%
Analyst coverage

Good

Last updated11 Oct 2024

Recent future growth updates

Recent updates

A Look At The Intrinsic Value Of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)

Oct 01
A Look At The Intrinsic Value Of China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)

Market Participants Recognise China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Earnings

Sep 12
Market Participants Recognise China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Earnings

Does China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Have A Healthy Balance Sheet?

Jul 25
Does China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Have A Healthy Balance Sheet?

China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) P/E Is On The Mark

Jun 12
China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) P/E Is On The Mark

China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Increasing Its Dividend To CN¥0.30

Apr 26
China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Increasing Its Dividend To CN¥0.30

Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?

Apr 22
Is China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Using Too Much Debt?

China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Conservative Accounting Might Explain Soft Earnings

Apr 01
China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Conservative Accounting Might Explain Soft Earnings

What Does The Future Hold For China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)? These Analysts Have Been Cutting Their Estimates

Mar 31
What Does The Future Hold For China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SZSE:300294)? These Analysts Have Been Cutting Their Estimates

Earnings and Revenue Growth Forecasts

SZSE:300294 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20262,2526916906937
12/31/20252,0436166215998
12/31/20241,8965607028567
6/30/20242,007228376460N/A
3/31/20242,295219458543N/A
12/31/20232,652237554642N/A
9/30/20232,866478609745N/A
6/30/20232,901479592761N/A
3/31/20232,910499647797N/A
12/31/20222,759432458596N/A
9/30/20222,722439459549N/A
6/30/20222,754426525578N/A
3/31/20222,6813471,1521,208N/A
12/31/20212,6513451,2771,345N/A
9/30/20212,6673601,2811,410N/A
6/30/20212,5862971,3331,474N/A
3/31/20212,528265669808N/A
12/31/20202,513260576719N/A
9/30/20202,664332533622N/A
6/30/20202,755374134228N/A
3/31/20202,867433-5938N/A
12/31/20192,909426-203-115N/A
9/30/20192,867501-369-286N/A
6/30/20192,735491-214-140N/A
3/31/20192,609486-110-34N/A
12/31/20182,388469-7935N/A
9/30/20182,30741921137N/A
6/30/20182,012390-39115N/A
3/31/20181,732362N/A-3N/A
12/31/20171,390357N/A-24N/A
9/30/20171,132316N/A21N/A
6/30/20171,085324N/A94N/A
3/31/2017994301N/A168N/A
12/31/2016947272N/A199N/A
9/30/2016839227N/A146N/A
6/30/2016720187N/A143N/A
3/31/2016615145N/A149N/A
12/31/2015543152N/A147N/A
9/30/2015498138N/A114N/A
6/30/2015472130N/A95N/A
3/31/2015452130N/A95N/A
12/31/2014438104N/A122N/A
9/30/201436696N/A112N/A
6/30/201432189N/A113N/A
3/31/201427885N/A93N/A
12/31/201324582N/A89N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300294's forecast earnings growth (31.2% per year) is above the savings rate (2.9%).

Earnings vs Market: 300294's earnings (31.2% per year) are forecast to grow faster than the CN market (23.7% per year).

High Growth Earnings: 300294's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300294's revenue (5.3% per year) is forecast to grow slower than the CN market (13.5% per year).

High Growth Revenue: 300294's revenue (5.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300294's Return on Equity is forecast to be low in 3 years time (7.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y